There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX) and AVEO Pharma (AVEO) with bullish sentiments.
Neurocrine (NBIX)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Neurocrine today and set a price target of $162. The company’s shares closed yesterday at $73.83, close to its 52-week low of $64.72.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.1% and a 42.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $114.29 average price target, implying a 54.8% upside from current levels. In a report issued on December 6, Cowen & Co. also maintained a Buy rating on the stock with a $115 price target.
.
See today’s analyst top recommended stocks >>
AVEO Pharma (AVEO)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AVEO Pharma, with a price target of $9. The company’s shares closed yesterday at $2.06.
Ramakanth commented:
“We maintain our Buy rating on AVEO and our 12-month price target of $9.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.5% discount rate and 3% terminal growth rate. We derive an rNPV of $1.5B for the products and add in cash and cash equivalents of $18M to arrive at a 12-month price target of $9.16 per diluted share, which we round to $9.00.”
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.3% and a 34.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AVEO Pharma with a $6.33 average price target, a 207.3% upside from current levels. In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $5 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
